ReviewSeminars in radiation oncology2023
Theranostics and Patient-Specific Dosimetry.
Review in Seminars in radiation oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Beyond the Fixed Dose in Theranostics: Pragmatic Dosimetry as the Missing Link in Optimizing Precision Nuclear Oncology.World journal of nuclear medicine · 2026Article
- Targeting Cytotoxic T-Cell Effector Function with Granzyme B PET: Translational Advances Toward Predicting Immunotherapy Outcomes.Molecular diagnosis & therapy · 2026Review
- Data-efficient unsupervised deep learning deformable SPECT/CT registration framework for voxel-level radionuclide therapy dosimetry: validation using clinicalEJNMMI physics · 2026Article
- Sharing a whole-/total-body [Scientific data · 2026Article
- Radiation Biology of Radiopharmaceuticals: Beyond External Beam Radiation Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Theranostics of Bone Metastases: The Role and Prospects of Bisphosphonate Radiopharmaceuticals.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Future of radiotheranostics.BMJ oncology · 2026Review
- Review
- Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2025Review
- Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatrace.International journal of radiation oncology, biology, physics · 2025Article
- Nuclear Insights in Nephrology: Echoes from 1975.Indian pediatrics · 2025Article
- Sharing a whole-/total-body [18F]FDG-PET/CT dataset with CT-derived segmentations: an ENHANCE.PET initiative.Research square · 2025Article
- Multi-scale computational modeling towards efficacy in radiopharmaceutical therapies while minimizing side effects: Modeling of amino acid infusion.PLoS computational biology · 2025Article
- New Approaches in Radiotherapy.Cancers · 2025Review
- 3D-Printed Organ-Realistic Phantoms to Verify Quantitative SPECT/CT Accuracy for 177Lu-PSMA-617 Treatment Planning.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Editorial for the Special Issue "Molecular Biology in Targeted Radionuclide Therapy Radiopharmaceutical Design".Current issues in molecular biology · 2024Article
- Aspects and prospects of preclinical theranostic radiopharmaceutical development.Theranostics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Radiopharmaceutical therapy (RPT) is an invigorated form of cancer therapy that systemically delivers targeted radioactive drugs to cancer cells. Theranostics is a type of RPT that utilizes imaging, either of the RPT drug directly or a companion diagnostic, to inform whether a patient will benefit from the treatment. Given the ability to image the drug onboard theranostic treatments also lends itself readily to patient-specific dosimetry, which is a physics-based process that determines the overall absorbed dose burden to healthy organs and tissues and tumors in patients. While companion diagnostics identify who will benefit from RPT treatments, dosimetry determines how much activity these beneficiaries can receive to maximize therapeutic efficacy. Clinical data is starting to accrue suggesting tremendous benefits when dosimetry is performed for RPT patients. RPT dosimetry, which was once performed by florid and often inaccurate workflows, can now be performed more efficiently and accurately with FDA-cleared dosimetry software. Therefore, there is no better time for the field of oncology to adopt this form of personalize medicine to improve outcomes for cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.